Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has worked hard but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the curing of multi-drug-resistant HIV happen to be closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my past few shares. My first CytoDyn post, “CytoDyn: What To Do When It’s Too Good In order to Be True?”, set away the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely marketing image in the Uptick Newswire interview which I came away with a poor viewpoint of the company.

Irony of irony, my poor impression of the company has grown steadily, although the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the technology and associated intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a level III clinical trial ($1.5 million) plus the first brand new drug program approval ($five million), as well as royalty payments of five % of net sales after commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many therapies and many indications, it’s this individual treatments in addition to a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an active organization with diverse interests albeit focused on leronlimab, several illness sorts, multiple delivering presentations in addition to multiple publications.

Could it all be smoke cigarettes and mirrors? That’s a question I’ve been asking myself with the really beginning of my interest in this particular business. Judging by way of the multiples of thousands of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this question.

CytoDyn is a traditional battleground, or some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *